Low-Dose Naltrexone Benefits: An Evidence-Based Guide to LDN's Clinical Uses

What Is Low-Dose Naltrexone?

Naltrexone is an opioid receptor antagonist originally FDA-approved in 1984 for the treatment of opioid use disorder, and subsequently for alcohol use disorder. At its standard approved dose of 50 mg/day, it blocks opioid receptors strongly enough to prevent opioid effects entirely—the basis of its addiction-treatment indication.

Low-dose naltrexone refers to the same molecule used at doses approximately 10–30 times lower, typically 1.5 mg to 4.5 mg/day. At these doses, the drug behaves very differently. Rather than producing sustained opioid receptor blockade, it briefly occupies opioid receptors and then dissociates, which triggers a compensatory upregulation of endogenous opioid signaling. It also acts on microglial cells in the central nervous system through a separate non-opioid mechanism, reducing neuroinflammation.

The combination of these two effects—endogenous opioid upregulation plus reduced neuroinflammation—is the basis for the broad range of off-label uses that have emerged over the past three decades.

LDN's use for these conditions is entirely off-label. It is not FDA-approved for fibromyalgia, multiple sclerosis, Crohn's disease, long COVID, or any of the other conditions discussed in this article. Off-label prescribing is legal and common in U.S. medicine, but it does mean that the evidence base is still developing for most of these indications.

How LDN Works: Two Mechanisms, One Drug

Mechanism 1: Transient Opioid Receptor Blockade

At low doses, naltrexone briefly occupies opioid receptors—typically for a few hours after a dose—before dissociating. The body interprets this brief blockade as a deficit and responds by upregulating production of endogenous opioids, including endorphins, enkephalins, and dynorphins.

These endogenous opioids interact with the body's natural pain regulation pathways, contributing to LDN's analgesic and mood-stabilizing effects. This is sometimes called the "opioid rebound" hypothesis: the body's response to brief blockade results in net increased opioid signaling [1].

Mechanism 2: Microglial Modulation Through TLR4

The second and increasingly emphasized mechanism is LDN's effect on microglial cells—the resident immune cells of the central nervous system.

Microglia express Toll-like receptor 4 (TLR4), a pattern recognition receptor that triggers inflammatory responses when activated. In conditions characterized by chronic neuroinflammation—including fibromyalgia, ME/CFS, long COVID, and certain forms of chronic pain—microglia become persistently activated, producing pro-inflammatory cytokines that amplify pain signaling and contribute to fatigue and cognitive symptoms.

LDN binds to TLR4 and dampens microglial activation. This reduces production of inflammatory cytokines including interleukin-1β, interleukin-6, and tumor necrosis factor-alpha. The net effect is reduced neuroinflammation and, downstream, reduced pain sensitization and improved quality of life across multiple inflammatory conditions [2].

The TLR4 mechanism likely accounts for the majority of LDN's clinical benefit in inflammatory and chronic pain conditions, though the contribution of each mechanism varies by condition.

For a deeper treatment of these mechanisms, see our foundational review of LDN's actions on inflammation and microglia.

The Main Clinical Benefits of LDN

The following sections cover the conditions for which LDN has the strongest clinical evidence, in approximate descending order of evidence strength. Evidence quality varies considerably across indications—some are supported by randomized controlled trials, others by case series and observational data.

1. Fibromyalgia

Fibromyalgia is the condition with arguably the strongest LDN evidence to date. The disorder is characterized by widespread chronic pain, fatigue, sleep disturbance, and cognitive symptoms—and current pharmacological options (pregabalin, duloxetine, milnacipran) provide modest benefit with substantial side effect burden.

Multiple controlled trials and several systematic reviews have evaluated LDN in fibromyalgia. A representative 2013 randomized crossover trial at Stanford found that LDN reduced fibromyalgia pain significantly more than placebo, with 32% of patients reporting clinically meaningful improvement [3]. Subsequent studies have replicated these findings, with consistent improvements in pain, sleep quality, fatigue, and global well-being.

The American Academy of Family Physicians has noted that LDN "reduces pain and improves sleep, fatigue, and cognitive symptoms in patients with fibromyalgia, making it a promising treatment option" [4]. Among the off-label conditions in this article, fibromyalgia has the most developed evidence base.

Typical dosing in fibromyalgia trials has ranged from 1.5 mg to 4.5 mg nightly.

2. Crohn's Disease and Inflammatory Bowel Disease

LDN has been studied in Crohn's disease for nearly two decades, with consistently positive results. A 2018 study in Journal of Translational Medicine found that LDN directly improved epithelial barrier function by promoting wound healing and reducing endoplasmic reticulum stress in inflamed gut mucosa [5]. The authors concluded that "low dose naltrexone treatment is effective and safe, and could be considered for the treatment of therapy refractory IBD patients."

Earlier randomized trials and case series have demonstrated improvements in clinical disease activity scores, endoscopic findings, and quality of life. Response rates in published Crohn's disease trials have generally fallen in the 60–80% range for clinical improvement, with a meaningful subset achieving full clinical remission.

For ulcerative colitis, the evidence is less developed than for Crohn's but generally favorable. LDN is increasingly considered a reasonable adjunct or alternative for patients with mild-to-moderate IBD who have not responded to or who wish to avoid biologic therapies.

For a complete treatment of LDN in inflammatory bowel disease and other chronic inflammatory conditions, see our review of LDN in chronic inflammatory diseases.

3. Multiple Sclerosis

Multiple controlled and observational studies have examined LDN in multiple sclerosis (MS), with consistent findings on quality-of-life and mental-health endpoints. A 2022 study by McLaughlin and colleagues found that MS patients on LDN—either as monotherapy or alongside disease-modifying therapy (DMT)—reported significantly lower levels of anxiety and depression during the COVID-19 pandemic compared to those on DMTs alone [6].

Earlier randomized trials demonstrated improvements in mental health–related quality of life and disability scores in MS patients on LDN. Whether LDN influences MS disease activity itself—as measured by relapse rate or new lesion formation on MRI—is less clearly established. The current consensus positions LDN as a useful adjunctive therapy for symptom management in MS, particularly for fatigue, mood, and quality-of-life parameters, rather than as a replacement for established disease-modifying therapies.

4. Long COVID (Post-Acute Sequelae of COVID-19)

LDN has emerged over the past three years as one of the more promising pharmacological options for long COVID, a condition that affects an estimated 43% of people who have had COVID-19 and for which there are very few evidence-based treatments.

A 2023 study examining LDN use in long COVID found significant benefits in reducing total symptom burden, functional status scores, and specific symptoms including fatigue, brain fog, post-exertional malaise, unrefreshing sleep, and headache [7]. The mechanism is biologically coherent: long COVID is increasingly understood as a condition involving persistent neuroinflammation and microglial activation, which is precisely the pathway LDN addresses.

Anecdotal reports from family medicine practice support the trial data. The AAFP commentary describes a patient with post-COVID syndrome and orthostatic symptoms who recovered enough function on LDN to resume martial arts training [4].

Larger randomized trials are now in progress. For a complete review of the long COVID evidence, see our comprehensive guide to LDN for long COVID.

5. Chronic Fatigue Syndrome (ME/CFS)

The overlap between long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is substantial, and the LDN evidence in ME/CFS predates and reinforces the long COVID findings. A 2021 study published in Frontiers in Immunology examined LDN's effects on natural killer cell function in ME/CFS patients through its action on TRPM3 calcium channels, finding restored ion flow and clinical improvement in fatigue symptoms [8].

Case series have consistently reported improvements in fatigue, sleep quality, post-exertional malaise, cognitive function, and mood in ME/CFS patients on LDN over months of treatment.

6. Complex Regional Pain Syndrome (CRPS) and Neuropathic Pain

CRPS is a chronic, often debilitating pain condition that frequently follows injury or trauma and is notoriously difficult to treat. A 2023 case series from a single institution found that 64% of patients with various pain disorders experienced some degree of pain relief with LDN, with the most significant responses among patients with neuropathic pain and CRPS [9].

For neuropathic pain conditions including diabetic neuropathy, post-herpetic neuralgia, and idiopathic small fiber neuropathy, the evidence remains primarily observational but generally favorable, with response rates in the 50–70% range for clinically meaningful improvement.

7. Postural Orthostatic Tachycardia Syndrome (POTS)

POTS is a form of dysautonomia characterized by an abnormal increase in heart rate upon standing, often accompanied by fatigue, brain fog, and exercise intolerance. The condition has become increasingly recognized in the wake of COVID-19, as a meaningful subset of long COVID patients develop POTS or POTS-like symptoms.

Evidence for LDN in POTS is primarily anecdotal and from case series, but the mechanism—reducing neuroinflammation that may drive autonomic dysfunction—is biologically plausible. Several specialists in dysautonomia and autonomic disorders now include LDN in their treatment armamentarium for POTS patients with significant inflammatory or post-viral components.

8. Mental Health: Depression, Anxiety, and Mood Disorders

A 2017 randomized double-blind pilot trial in patients with major depressive disorder found that LDN augmentation (1 mg twice daily for three weeks) significantly reduced depressive symptoms in individuals who had relapsed while on antidepressants [10]. Anxiety findings from the MS literature (described above) point in the same direction.

LDN's effects on mood are believed to be mediated by both the endogenous opioid system (with its effects on reward and well-being) and the anti-neuroinflammatory mechanism (given the increasing evidence that depression involves a neuroinflammatory component). The clinical role is generally as an adjunct to standard antidepressant therapy in treatment-resistant cases, rather than a first-line treatment.

9. Other Emerging Applications

LDN is being studied or used clinically for a growing range of additional conditions:

• Autoimmune skin conditions including Hailey-Hailey disease, lichen planopilaris, and certain forms of psoriasis
• Endometriosis and chronic pelvic pain, with several ongoing trials
• Hashimoto's thyroiditis and other autoimmune thyroid conditions, with mixed but generally favorable observational data
• Cancer-related fatigue, with preliminary trials underway
• Mast cell activation syndrome (MCAS), where neuroinflammation may overlap with mast cell pathology
• Sjögren's syndrome and other connective tissue disorders

For a broader treatment of LDN's range of applications in chronic disease, see our foundational review of LDN in chronic disease management.

What LDN Has Not Been Proven to Do

A responsible evidence-based article needs to be specific about what the current evidence does not yet show.

LDN has not been demonstrated to cure any of the conditions for which it is used. The benefits are improvements in symptoms, quality of life, and functional status—not disease elimination. For autoimmune conditions, LDN is generally an adjunct to or symptomatic management alongside conventional treatment, not a replacement.

Evidence quality varies considerably across indications. Fibromyalgia and Crohn's disease have stronger evidence than POTS or mast cell activation syndrome. Patients and clinicians should calibrate expectations accordingly.

Response rates are not universal. Across the conditions discussed, response rates typically range from 40–70%, meaning a substantial minority of patients do not benefit. There is no reliable predictor of who will respond.

Optimal dosing and dosing schedules remain partially open. Most protocols use 1.5–4.5 mg nightly, but some patients respond better to morning dosing, divided dosing, or different total daily amounts. Individual titration is often necessary.

Long-term safety beyond several years of continuous use is not yet established by formal trials. Clinical experience over decades suggests sustained safety, but formal long-term data is limited.

LDN does not work for everyone in any of these conditions. Even fibromyalgia, with the strongest evidence base, shows roughly 30–40% non-response in trials. Patients who do not respond within 2–3 months of adequate dosing generally discontinue.

Side Effects and Safety

LDN's safety profile is one of its most distinguishing features. Compared with most other medications used for the conditions discussed in this article, LDN has notably few side effects, and serious adverse events are rare at typical low doses.

Commonly reported side effects:

• Vivid dreams or sleep disturbance (most common, especially in the first 1–2 weeks; often resolves with continued use or morning dosing)
• Headache (typically transient)
• Gastrointestinal symptoms (nausea, occasionally diarrhea, usually mild)
• Fatigue or dizziness (uncommon)
• Anxiety or restlessness (uncommon, sometimes responds to lower starting dose)

Important interactions and contraindications:

• Concurrent opioid use is the primary contraindication. Patients taking prescription opioids for pain management cannot start LDN without first transitioning off opioids under physician supervision. The opioid blockade, even at low doses, can precipitate withdrawal.
• Active opioid use disorder is a contraindication for the same reason.
• Pregnancy and breastfeeding: insufficient safety data, generally avoided.
• Acute hepatitis or severe liver disease: caution; LDN is hepatically metabolized.

Side effects, when they occur, are typically far more common at the higher doses used for addiction treatment (50 mg) than at the 1.5–4.5 mg doses used off-label. Most patients tolerate LDN well over months to years of continuous use.

Common Dosing Approaches

LDN dosing is generally individualized through titration. Common starting and target regimens include:

Approach - Starting Dose - Target Dose - Notes

• Standard: 1.5 mg nightly - 4.5 mg nightly - Most common; titrate weekly
• Slow titration: 0.5 mg nightly - 4.5 mg nightly - For sensitive patients; titrate every 1–2 weeks
• Divided dosing: 1.5 mg twice daily - 4.5 mg twice daily - Some patients respond better to split doses
• Morning dosing: 1.5 mg morning - 4.5 mg morning - Alternative for patients with vivid dreams
• Low-low dose: 0.5 mg nightly - 1.5–2 mg nightly - For highly sensitive patients or chronic fatigue

LDN is typically prepared by 503A compounding pharmacies, since the FDA-approved naltrexone strengths (50 mg) are far higher than off-label use requires. Capsule strengths of 0.5 mg, 1.5 mg, 3 mg, and 4.5 mg are commonly compounded.

Troche delivery (sublingual lozenges) is an emerging alternative to oral capsules, offering more predictable absorption and potentially faster onset. For a detailed treatment of troche delivery, see our research review on LDN troche delivery.

Who Should and Shouldn't Consider LDN

LDN may be reasonable to discuss with a qualified clinician for adults with:

• Fibromyalgia, with inadequate response to standard treatment
• Crohn's disease or ulcerative colitis, with mild-to-moderate activity or as an adjunct
• Multiple sclerosis, particularly for fatigue, mood, or quality-of-life symptoms
• Long COVID, particularly with prominent fatigue, brain fog, or post-exertional malaise
• ME/CFS
• Chronic pain conditions including CRPS or neuropathic pain
• Certain autoimmune conditions where conventional treatments have failed or are not tolerated

LDN is not appropriate for:

• Patients currently taking prescription opioids for pain
• Patients with active opioid use disorder
• Pregnancy or breastfeeding
• Significant active liver disease

Patients on partial agonists like buprenorphine or tramadol require careful evaluation by the prescribing clinician before LDN can be considered.

Frequently Asked Questions

What is low-dose naltrexone used for?

LDN is used off-label for a range of inflammatory, autoimmune, and chronic pain conditions, with the strongest evidence for fibromyalgia, Crohn's disease, multiple sclerosis, long COVID, and chronic fatigue syndrome (ME/CFS). It is also used for complex regional pain syndrome, neuropathic pain, POTS, and certain autoimmune skin conditions. All use for these conditions is off-label; LDN is FDA-approved only at the higher 50 mg dose for opioid and alcohol use disorder.

How is LDN different from naltrexone?

They are the same medication. LDN refers to the use of naltrexone at doses of 1.5–4.5 mg/day, roughly 10–30 times lower than the FDA-approved 50 mg/day dose for addiction treatment. At low doses, the drug acts primarily through transient opioid receptor blockade and microglial modulation, producing very different clinical effects than the sustained opioid blockade seen at the standard 50 mg dose.

What conditions does LDN treat?

The conditions with the most clinical evidence are fibromyalgia, Crohn's disease, multiple sclerosis, long COVID, and ME/CFS. Emerging evidence supports use in complex regional pain syndrome, neuropathic pain, certain autoimmune conditions, POTS, and treatment-resistant depression. LDN is most useful for conditions where neuroinflammation contributes to the disease process.

How long does LDN take to work?

This varies by condition. For sleep and mood symptoms, some patients report changes within 1–2 weeks. For pain conditions like fibromyalgia, meaningful improvement typically takes 4–8 weeks. For autoimmune and inflammatory conditions, the full effect may take 3–6 months. Patients who do not respond within 3 months of adequate dosing usually discontinue.

Is LDN safe for long-term use?

LDN has a favorable safety profile at typical low doses, with serious adverse events rarely reported. Clinical experience suggests it can be used safely for many years in patients who tolerate it well. Periodic monitoring with a prescribing clinician is recommended but laboratory monitoring requirements are minimal compared to most chronic medications.

What are the side effects of LDN?

The most common side effect is vivid dreams or sleep disturbance, particularly in the first 1–2 weeks, often resolving with continued use or by switching to morning dosing. Less common side effects include headache, mild gastrointestinal symptoms, transient fatigue, and dizziness. Side effects are uncommon at low doses and far more frequent at the 50 mg dose used for addiction treatment.

Does LDN work for fibromyalgia?

Yes, with the strongest evidence of any LDN indication. Randomized controlled trials have demonstrated significant improvements in pain, sleep, fatigue, and cognitive symptoms. Approximately 30–60% of fibromyalgia patients experience clinically meaningful improvement, often within 4–8 weeks.

Does LDN help with autoimmune disease?

Yes, for several autoimmune conditions. Evidence is strongest for Crohn's disease and multiple sclerosis. Emerging evidence supports use in Hashimoto's thyroiditis, certain forms of lupus, and autoimmune skin conditions. LDN is generally used as an adjunct to or alongside conventional disease-modifying treatment, not as a replacement.

Can LDN help with long COVID?

Yes, based on growing observational evidence. A 2023 study found significant improvements in total symptom burden, fatigue, brain fog, post-exertional malaise, unrefreshing sleep, and headache in long COVID patients on LDN. The mechanism—reducing neuroinflammation through microglial modulation—aligns with the emerging understanding of long COVID pathophysiology. Larger randomized trials are in progress.

Is LDN available without a prescription?

No. LDN is a prescription-only medication in the United States and most countries. It is typically prepared by 503A compounding pharmacies in custom low-dose strengths because the commercially available 50 mg tablets are far higher than the low-dose use requires.

Can I take LDN with my other medications?

LDN has relatively few drug interactions, but the primary contraindication is concurrent prescription opioid use. Patients on opioid pain medications cannot start LDN without first transitioning off the opioid. Patients on partial agonists like buprenorphine or tramadol need careful evaluation. Most other medications, including most antidepressants, anti-inflammatories, biologics, and DMARDs, are compatible with LDN—but all concurrent medications should be reviewed with the prescribing clinician.

What's the best time of day to take LDN?

Most protocols use nightly dosing because LDN was historically observed to work well taken at bedtime. However, patients who experience vivid dreams or sleep disturbance often do better with morning dosing, with equal efficacy. There is no single "correct" timing; individualization is the norm.

Does LDN cause weight loss?

LDN itself is not used or marketed for weight loss. (A different formulation—Contrave—combines naltrexone with bupropion for weight loss at higher naltrexone doses.) Some patients on LDN report modest weight loss, possibly related to reduced inflammation, but this is not a primary or reliable effect.

Can LDN help with depression and anxiety?

Yes, particularly as adjunctive therapy. A 2017 randomized trial demonstrated significant reduction in depressive symptoms when LDN was added to existing antidepressant therapy in patients who had relapsed. Anxiety improvements have been documented in MS patients. LDN is generally not used as first-line treatment for depression but can be useful in treatment-resistant cases or alongside standard antidepressants.

Where can I get LDN?

LDN is available through physicians familiar with its off-label use, including some primary care physicians, rheumatologists, neurologists, gastroenterologists, integrative medicine practitioners, and longevity-focused telemedicine providers. The prescription is typically filled at a 503A compounding pharmacy. Healthspan offers LDN under physician supervision through our LDN Protocol.

Does insurance cover LDN?

Insurance coverage for off-label LDN is variable. Some insurance plans cover compounded LDN when prescribed for specific conditions; many do not. Cash prices for compounded LDN at 503A pharmacies typically run $30–$80/month, making it relatively affordable even without coverage.

How Healthspan Approaches LDN

The Healthspan LDN Protocol provides physician-supervised access to low-dose naltrexone with personalized dose titration, ongoing monitoring, and consideration of each patient's specific condition and concurrent medications. Our approach includes:

• Baseline health and medication review to confirm LDN is appropriate
• Individualized starting dose and titration plan
• Compounded LDN dispensed through licensed U.S. pharmacies
• Ongoing physician oversight and dose adjustment based on response and tolerability
• Coordination with other prescribers for patients managing complex conditions

We are one of several legitimate options for U.S. patients seeking access to LDN under medical supervision. The right path depends on individual circumstances—existing physician relationships, condition being treated, and preferred care model.

Conclusion

Low-dose naltrexone occupies an unusual place in modern medicine: a decades-old, inexpensive, well-tolerated medication with growing evidence across a remarkable range of conditions—yet still unfamiliar to many physicians and rarely the first option suggested for the conditions it most reliably helps.

The evidence base has matured substantially over the past decade. For fibromyalgia, Crohn's disease, and multiple sclerosis, the data supports LDN as a reasonable component of treatment for many patients. For long COVID and ME/CFS, the evidence is rapidly growing and increasingly compelling. For other indications, the evidence is more preliminary but generally favorable, and the favorable safety profile makes a trial of treatment reasonable in many cases.

What LDN offers is not a cure for the conditions it treats. It offers meaningful symptom improvement and quality-of-life gains for a substantial proportion of patients with conditions where conventional treatments are often inadequate. For patients with chronic inflammatory, autoimmune, or pain conditions who have not found adequate relief from standard treatments—or who want to avoid the side effect burden of those treatments—LDN is increasingly recognized as worth a careful, physician-supervised trial.

Related Research

• The Multidimensional Benefits of Low-Dose Naltrexone: Pain, Fatigue, and Mental Health
• LDN for Long COVID: A Comprehensive Relief Guide
• Understanding LDN's Impact on Chronic Inflammatory Diseases
• Low-Dose Naltrexone in Chronic Disease Management: A Healthspan Review
• LDN Troche Delivery: A Research Review